Clinical trial · no report yet · Phase 3
NCT05116189
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
- NCT05116189 ↗
- Active not recruiting
- Merck Sharp & Dohme LLC
- 73 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 34 | |
| Podcasts | 23 | |
| X threads | 16 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Ovarian Cancer; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms
- Interventions
- Pembrolizumab; Paclitaxel; Bevacizumab; Placebo for pembrolizumab; Docetaxel
- Arms
- Pembrolizumab + paclitaxel ± bevacizumab · Experimental
- Placebo + paclitaxel ± bevacizumab · Placebo comparator
- Enrollment
- 643
- Primary outcomes
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥1)
- PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Dec 13, 2021
- Primary completion
- Mar 5, 2025
- Results posted
- Yes
- Registry record
- NCT05116189 · updated Mar 9, 2026
Publications
linked from the registry- Lesnock JL, Temin S, Bouberhan S, Adams SF, Barber EL, Burkett WC, Corrales L, Fuh KC, Fujiwara K, Hardesty MM, Lefkowits C, Richardson K, Rimel BJ, Ring KL, Rocconi RP, Rungruang BJ, Scalici JM. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol. 2026 Oct;44(28):2725-2744. doi: 10.1200/JCO-26-01591. Epub 2026 Jul 13. PubMed 42441925
- Colombo N, Zsiros E, Parma G, Rulli E, Sebastianelli A, Bidzinski M, Gallardo C, Matanes E, Hasegawa K, Kose F, Magallanes-Maciel M, Herbertson RA, Ananda S, Kroep JR, de Melo AC, Debruyne PR, Kim JW, Sehouli J, Pierre ME, Hietanen S, Zamagni C, Lu X, Monk BJ, Coleman RL, Peng X, Yamada K, Bogusz AM, De La Motte Rouge T, Wu X; ENGOT-ov65/KEYNOTE-B96 investigators. Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2026 Apr 18;407(10538):1525-1537. doi: 10.1016/S0140-6736(26)00602-1. Epub 2026 Apr 10. PubMed 41974150
- Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3. PubMed 37185961